LEVOFLOXACIN IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA: WHETHER ADVANTAGES ARE OBVIOUS?


Cite item

Full Text

Abstract

The article presents the data on epidemiological studies of community-acquired pneumonia (CAP). The problems of growth of antibiotic resistance of major pathogens of respiratory tract infections in 1995-2009 are discussed. Comparison of the effectiveness of monotherapy with respiratory fluoroquinolones or combination of β-lactam antibiotic and macrolide in the initial treatment of CAP is of great interest.

References

  1. Чучалин А.Г., Синопальников А.И., Козлов Р.С. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике / Пособие для врачей. М., 2010. 106 с.
  2. Mandell LA, Wunderlink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(2):S27-72.
  3. Падейская Е.Н. Левофлоксацин (Таваник) - препарат группы фторхинолонов для лечения инфекционных заболеваний с широкими показаниями к применению // Качественная клиническая практика 2002. № 2. С. 80-95.
  4. Сидоренко С.В. Фторированные хинолоны - спектр активности и клиническое значение // Клин. антибиотикотер. 2001. № (5-6). С. 31-5.
  5. Paladino JA. Is more than one quinolone needed in clinical practice. Ann Pharmacother 2001;35:1085-95.
  6. Tavanic (levofloxacin) iv/oral. Scientific Product Monograph. Hoechst-Marion Russel, 1999.
  7. Davis R, Bryson HM. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994;47:677-700.
  8. Fu KP, Foleno B, Rosenthale ME. The postantibiotic suppressive effect of L-ofloxacin, an optically active isomer of ofloxacin. Diagn Microbiol Infect Dis 1992;15:375-78.
  9. Licata L, Smith CE, Goldshmidt RM, et al. Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother 1997;41:950-55.
  10. Spangler SK, Lin G, Jacobs MR, et al. Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin and clarithromycin against 20 pneumococci. Antimicrob Agents Chemother 1998;42(5):1253-55.
  11. Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 2003;63(24):2769-802.
  12. Сидоренко С.В. Тенденции в распространении антибиотикорезистентности среди возбудителей внебольничной инфекции на территории Российской Федерации //Consilium medicum 2007. № 1. Т. 09.
  13. Brown SD, Rybak MJ. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study. J Antimicrob Chemother 2004;54(1):i7-15.
  14. Doern GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. J Infect 2004;48(1):56-65.
  15. Goff DA, Dowzicky MJ. Prevalence and regional variation in meticillin-resistant Staphylococcus aureus (MRSA) in the USA and comparative in vitro activity of tigecycline, a glycylcycline antimicrobial. J Med Microbiol 2007;56(9):1189-195.
  16. Jacobs MR, Felmingham D, Appelbaum PC, et al. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003;52(2):229-46.
  17. Jones RN, Fritsche TR, Sader HS, et al. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values. Diagn Microbiol Infect Dis 2007;58 (1):9-17.
  18. Karlowsky JA, Thornsberry C, Critchley IA, et al. Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. Antimicrob Agents Chemother 2003;47(6):1790-97.
  19. Salkind AR, Cuddy PG, Foxworth JW. Fluoroquinolone treatment of community-acquired pneumonia: a meta-analysis. Ann Pharmacother 2002;36:1938-43.
  20. Vardakas KZ, Siempos II, Grammatikos A, et al. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized clinical trials. CMAJ 2008;179(12):1269-77.
  21. Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России в 1999-2005 гг.: результаты многоцентровых проспективных исследований ПеГАС-I и ПеГАС-II // Клин. биол. и антимикроб. химиотер. 2006. № 1 (8). С. 33-47.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies